NO20030812D0 - Bifenylderivater og anvendelse derav som integrininhibitorer - Google Patents

Bifenylderivater og anvendelse derav som integrininhibitorer

Info

Publication number
NO20030812D0
NO20030812D0 NO20030812A NO20030812A NO20030812D0 NO 20030812 D0 NO20030812 D0 NO 20030812D0 NO 20030812 A NO20030812 A NO 20030812A NO 20030812 A NO20030812 A NO 20030812A NO 20030812 D0 NO20030812 D0 NO 20030812D0
Authority
NO
Norway
Prior art keywords
biphenyl derivatives
integrin inhibitors
integrin
inhibitors
biphenyl
Prior art date
Application number
NO20030812A
Other languages
English (en)
Norwegian (no)
Other versions
NO20030812L (no
Inventor
Wolfgang Staehle
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20030812D0 publication Critical patent/NO20030812D0/no
Publication of NO20030812L publication Critical patent/NO20030812L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
NO20030812A 2000-08-23 2003-02-21 Bifenylderivater og anvendelse derav som integrininhibitorer NO20030812L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10041428A DE10041428A1 (de) 2000-08-23 2000-08-23 Biphenylderivate
PCT/EP2001/008514 WO2002016323A1 (de) 2000-08-23 2001-07-24 Biphenylderivate und ihre verwendung als intigrininhibitoren

Publications (2)

Publication Number Publication Date
NO20030812D0 true NO20030812D0 (no) 2003-02-21
NO20030812L NO20030812L (no) 2003-02-21

Family

ID=7653542

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030812A NO20030812L (no) 2000-08-23 2003-02-21 Bifenylderivater og anvendelse derav som integrininhibitorer

Country Status (17)

Country Link
US (1) US20030187289A1 (xx)
EP (1) EP1311484A1 (xx)
JP (1) JP2004506717A (xx)
KR (1) KR20030022419A (xx)
CN (1) CN1447795A (xx)
AU (1) AU8973201A (xx)
BR (1) BR0113373A (xx)
CA (1) CA2420205A1 (xx)
CZ (1) CZ2003670A3 (xx)
DE (1) DE10041428A1 (xx)
HU (1) HUP0302822A3 (xx)
MX (1) MXPA03001556A (xx)
NO (1) NO20030812L (xx)
PL (1) PL359154A1 (xx)
SK (1) SK2952003A3 (xx)
WO (1) WO2002016323A1 (xx)
ZA (1) ZA200302253B (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10127041A1 (de) * 2001-06-02 2002-12-05 Merck Patent Gmbh Integrinantagonisten
JP2019533139A (ja) 2016-09-08 2019-11-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ネフローゼ症候群を診断及び処置するための方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2221227T3 (es) * 1997-11-24 2004-12-16 MERCK & CO., INC. Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular.
AU3561099A (en) * 1998-04-14 1999-11-01 American Home Products Corporation Acylresorcinol derivatives as selective vitronectin receptor inhibitors
EP0960882A1 (en) * 1998-05-19 1999-12-01 Hoechst Marion Roussel Deutschland GmbH Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists

Also Published As

Publication number Publication date
DE10041428A1 (de) 2002-03-07
CN1447795A (zh) 2003-10-08
EP1311484A1 (de) 2003-05-21
AU8973201A (en) 2002-03-04
HUP0302822A3 (en) 2004-07-28
KR20030022419A (ko) 2003-03-15
WO2002016323A1 (de) 2002-02-28
CZ2003670A3 (cs) 2003-06-18
ZA200302253B (en) 2004-06-28
HUP0302822A2 (hu) 2003-12-29
NO20030812L (no) 2003-02-21
US20030187289A1 (en) 2003-10-02
JP2004506717A (ja) 2004-03-04
SK2952003A3 (en) 2003-06-03
MXPA03001556A (es) 2003-06-06
BR0113373A (pt) 2003-07-15
PL359154A1 (en) 2004-08-23
CA2420205A1 (en) 2003-02-21

Similar Documents

Publication Publication Date Title
IS6934A (is) Nýjar spírótrísýklískar afleiður og notkun þeirrasem fosfódíesterasa-7-hindrar
NO20026010D0 (no) Substituerte quinazolinderivater og deres anvendelse som inhibitorer
DK1282611T3 (da) Substituerede phenylacetatamider og anvendelse deraf som glucokinaseaktivatorer
DK1246802T3 (da) 4-aminopicolinater og deres anvendelse som herbicider
DK1133477T3 (da) Substituerede benzimidazoler og deres anvendelse som parpinhibitorer
NO20030867D0 (no) Hydroksamderivater anvendelig som deacetylaseinhibitorer
DK1648426T3 (da) Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer
NO20012688L (no) Benzamidderivater og anvendelse derav som APOB-100 sekresjonsinhibitorer
NO20053356L (no) Aminindazolderivater og anvendelse derav som kinaseinhibitorer.
NO20032830D0 (no) Tetrahydropyridinderivater, fremstilling derav og anvendelse som celle-proliferasjonsinhibitorer
NO20025357L (no) Antranylamider og deres anvendelse som legemidler
DK1170288T3 (da) Diphenylurinstofderivater og deres anvendelse som alfa2/5-HT2c-antagonister
NO20025150L (no) 2-acylindolderivater og deres anvendelse som antitumormidler
NO20042719L (no) Substituerte 2-amino-cykloalkankarboksamider og deres anvendelse som protease-inhibitorer
NO20025504L (no) Nye tiokromanderivater og anvendelse derav som trombininhibitorer
DK1343764T3 (da) Urinstof og urethanderivater som integrininhibitorer
NO20030243D0 (no) Nye forbindelser og deres anvendelse som glysintransportinhibitorer
NO20030998D0 (no) Arylpiperazinderivater og deres anvendelse som psykotropiske midler
NO20030813D0 (no) Bifenylderivater og deres anvendelse som integrininhibitorer
NO20023951D0 (no) Arylpiperaziner og arylpiperidiner og deres anvendelse som metalloproteinaseinhiberende midler
NO20025884L (no) 2-aminotiazolinderivater og deres anvendelse som NO- syntaseinhibitorer
NO20030812D0 (no) Bifenylderivater og anvendelse derav som integrininhibitorer
NO20020592D0 (no) Fluorenderivater som integrininhibitorer
NO20025885D0 (no) 4,5-dihydro-tiazol-2-ylaminderivater og deres anvendelse som NO-syntaseinhibitorer
DK1202969T3 (da) Biphenylderivater, deres fremstilling og deres anvendelse som MTP-inhibitor